

**POSTER PRESENTATION**

**Open Access**

# Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

Elixabet Bolaños-Mateo<sup>1\*</sup>, Bettina Weigelin<sup>2</sup>, Alvaro Teixeira<sup>3</sup>, Ivan Martinez-Forero<sup>3</sup>, Sara Labiano<sup>1</sup>, Arantza Azpilicueta<sup>1</sup>, Aizea Morales-Kastresana<sup>4</sup>, Jose I Quetglas<sup>3</sup>, Esther Wagena<sup>2</sup>, Alfonso Rodriguez<sup>1</sup>, Lieping Chen<sup>5</sup>, Peter Friedl<sup>2</sup>, Ignacio Melero<sup>1</sup>

From Society for Immunotherapy of Cancer 29th Annual Meeting  
National Harbor, MD, USA. 6-9 November 2014

B16-derived OVA-expressing melanomas resist curative immunotherapy with either adoptive transfer of activated anti-OVA OT1 cytotoxic T lymphocytes (CTLs) or agonist anti-CD137 (4-1BB) mAb. However when acting in synergistic combination, these treatments consistently achieve tumor eradication. Tumor-infiltrating lymphocytes that accomplish tumor rejection exhibit enhanced effector function in both transferred OT-1 and endogenous CTLs. This is consistent with higher levels of expression of eomesodermin in CTLs and with confocal microscopy evidence for more efficacious tumor-cell killing. Combined immunotherapy of tumors monitored by intravital live-cell two-photon microscopy reveals persistence of the OT1 CTL-effector phenotype over prolonged periods of time. Anti-CD137 mAb delayed loss of function with focused and confined interaction kinetics of OT-1 CTL with target cells lasting up to ten days post-transfer. The synergy of adoptive T cell therapy and anti-CD137 mAb thus results from in-vivo enhancement of effector functions.

#### Authors' details

<sup>1</sup>Center for Applied Medical Research, Pamplona, Spain. <sup>2</sup>Radboud University Nijmegen, Nijmegen, Netherlands. <sup>3</sup>CIMA, University of Navarra, Pamplona, Spain. <sup>4</sup>NIH - National Cancer Institute, Bethesda, MD, USA. <sup>5</sup>Yale University, New Haven, CT, USA.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P95

Cite this article as: Bolaños-Mateo et al.: Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P95.

#### Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>Center for Applied Medical Research, Pamplona, Spain  
Full list of author information is available at the end of the article